venture capital
Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs
Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies
Getting to Yes: How Deal-Making Fuels Biotech Growth – 2025 Updates
biotech dealmaking; mergers and acquisitions; licensing; venture capital; BATNA; pharmaceutical negotiations; reputation; pipeline gaps; patent cliffs; valuation; regulatory uncertainty
Sanofi Injects $625M Into Biotech Investment Arm to Accelerate Innovation
Sanofi; Sanofi Ventures; biotech investment; $625M cash infusion; digital health; immunology; rare diseases; neurology; venture capital; cell/gene therapy; portfolio expansion
Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M
Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials
Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology
T.Rx Capital; Robert Langer; Michael Langer; intersection of technology and biology; biotech investments; venture capital; Fund I
Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M
CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development
Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success
Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I
Frazier Life Sciences Raises $1.3 Billion Amid Biotech Downturn
Frazier Life Sciences; venture capital; biotech; $1.3 billion raise; early-stage investments; biopharmaceutical startups; oversubscribed fund; therapeutics